Polycystic Ovary Syndrome (PCOS): History of Treatment Over Decades

What PCOS Is and Why Its Treatment History Is Complicated

PCOS is the most common endocrine disorder in women of reproductive age, affecting 8 to 13 percent of women worldwide. It is not a single disease. It is a syndrome defined by at least two of three Rotterdam criteria: irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound.

That heterogeneity is exactly why treatment history is messy. Clinicians in each decade tended to treat the symptom most visible to them, often without understanding the underlying metabolic driver. A gynecologist in 1950 saw anovulation and irregular periods. An endocrinologist in 1980 saw androgen excess. A metabolic physician in 1995 saw insulin resistance. Each generated a different treatment lineage, and women bore the cost of those silos.

The Diagnostic Criteria Kept Changing

The National Institutes of Health defined PCOS in 1990 around hyperandrogenism and chronic anovulation only. The Rotterdam consensus in 2003 broadened the definition to include polycystic morphology, creating four phenotypes. The Androgen Excess Society then pushed back in 2006, arguing androgen excess must be present. ACOG Practice Bulletin 194 (2018) currently uses the Rotterdam criteria for diagnosis while acknowledging ongoing debate.

Every time the definition shifted, so did who was counted as having PCOS, who was enrolled in trials, and which treatment looked "effective." Women without androgen excess had different outcomes with the same drugs. This is not just academic history; it explains why older studies are hard to apply to your specific phenotype today.

The Surgical Era: Ovarian Wedge Resection (1935 to 1960s)

The first formal treatment for what we now call PCOS was surgery. In 1935, Irving Stein and Michael Leventhal described seven women with bilateral polycystic ovaries, amenorrhea, hirsutism, and obesity. They performed bilateral ovarian wedge resection, removing roughly one-third of each ovary, and reported resumption of menstrual cycles in all seven women.

Why It Worked (Partially)

Wedge resection reduces androgen-producing ovarian stroma. Androgen levels fall acutely, and the hypothalamic-pituitary axis, no longer suppressed by excess androgens and estrone, resumes pulsatile GnRH secretion. Ovulation rates of 80 to 90 percent were reported in early series, with pregnancy rates around 50 to 60 percent in selected women.

Why It Was Abandoned

Open wedge resection carries real risks: postoperative adhesions affecting tubal function in up to 30 percent of cases, bleeding, and infection. As medical alternatives emerged in the 1960s, surgical rates declined. The technique did not disappear entirely. Laparoscopic ovarian drilling, introduced in the 1980s as a minimally invasive descendant, uses electrocautery or laser to create 4 to 10 punctures per ovary, achieving ovulation in 54 to 76 percent of clomiphene-resistant women with fewer adhesion risks than open surgery.

The Hormonal Era: Oral Contraceptives and Androgen Suppression (1960s to 1990s)

Combined oral contraceptives became available in 1960 and were quickly applied to PCOS, not for contraception but for cycle regulation and androgen suppression. The synthetic estrogen component increases sex hormone-binding globulin (SHBG), which binds free testosterone. The progestin component suppresses LH-driven androgen production from the ovary. Together they reduce free androgens by 40 to 70 percent, improving acne and hirsutism.

What Was Gained

For women who were not trying to conceive, the combined pill addressed the two most distressing symptoms: irregular bleeding and androgen-driven skin changes. It also provided endometrial protection against hyperplasia, a real risk in chronically anovulatory women whose endometrium is exposed to unopposed estrogen.

What Was Missed

The pill does nothing for insulin resistance, which affects 50 to 70 percent of women with PCOS regardless of weight. Some progestins, particularly older androgenic ones like levonorgestrel and norethindrone, worsen glucose metabolism and lipid profiles. Women on the pill had their cycles regulated on paper while their metabolic risk quietly accumulated. Clinicians of this era largely did not screen for insulin resistance, impaired glucose tolerance, or dyslipidemia in women with PCOS.

Spironolactone Enters the Picture

Spironolactone, an aldosterone antagonist with antiandrogen properties, began to be used off-label for PCOS hirsutism and acne from the 1970s onward. At doses of 50 to 200 mg per day it blocks androgen receptors in the skin and weakly suppresses adrenal androgen synthesis. It remains a first-line antiandrogen for women with PCOS today, particularly those who cannot or do not want to take estrogen-containing contraceptives. Because spironolactone is teratogenic to male fetuses, reliable contraception is required for any woman who is not post-menopausal while taking it.

The Fertility Treatment Era: Clomiphene Citrate (1967 to 2014)

Clomiphene citrate, a selective estrogen receptor modulator, received FDA approval for ovulation induction in 1967. For almost fifty years it was the first-line pharmacological treatment for anovulatory infertility in PCOS. It acts by blocking estrogen receptors in the hypothalamus, which the brain interprets as low estrogen, triggering increased FSH secretion and follicular development.

Clomiphene's Actual Numbers

In well-selected women with PCOS and no other infertility factors, clomiphene produces ovulation in approximately 73 percent of cycles and pregnancy in roughly 36 percent of women over six cycles. Those numbers are real but not as impressive as early enthusiasm suggested. Around 15 to 20 percent of women are clomiphene-resistant, defined as failure to ovulate after 150 mg per day.

The Letrozole Shift

Letrozole, an aromatase inhibitor developed for breast cancer, produces ovulation by a different mechanism: it blocks conversion of androgens to estrogen, causing a transient FSH rise without the anti-estrogenic effect on the endometrium that clomiphene produces. In the landmark New England Journal of Medicine trial by Legro et al. (2014) of 750 women with PCOS, letrozole produced a live-birth rate of 27.5 percent versus 19.1 percent with clomiphene, a difference that was statistically significant. ASRM now recommends letrozole as first-line ovulation induction for women with PCOS, superseding clomiphene's 47-year reign.

The Metabolic Turn: Metformin and Insulin Sensitization (Mid-1990s Onward)

The recognition that insulin resistance is central to PCOS pathophysiology, rather than a secondary feature, changed everything. Hyperinsulinemia directly stimulates ovarian theca cells to produce excess androgens, suppresses SHBG, and disrupts normal follicular selection. Treating the insulin problem, the reasoning went, should treat the syndrome at its root.

Metformin in PCOS

Metformin, a biguanide used for type 2 diabetes since the 1950s in Europe and FDA-approved in the US in 1994, was applied to PCOS off-label by the mid-1990s. Early trials showed reductions in fasting insulin, testosterone, and LH, with resumption of ovulation in some women. A Cochrane review of metformin for PCOS found it improves menstrual regularity and reduces androgen levels compared to placebo, but is less effective than letrozole or clomiphene for ovulation induction as a single agent.

What Metformin Actually Does Well

For women with PCOS who are not trying to conceive, metformin addresses metabolic risk that no hormonal treatment touches. Women with PCOS have approximately a three-fold higher risk of type 2 diabetes compared to age-matched women without PCOS. Metformin at doses of 1,500 to 2,000 mg per day reduces fasting glucose, improves insulin sensitivity measured by HOMA-IR, and may reduce the progression from impaired glucose tolerance to type 2 diabetes. It also reduces total and LDL cholesterol modestly.

Metformin Combined With Ovulation Induction

Adding metformin to clomiphene in clomiphene-resistant women increases the ovulation rate from roughly 27 percent to over 50 percent in some series. ACOG recommends metformin be considered as an adjunct to clomiphene or letrozole in women with PCOS who have not responded to first-line ovulation induction alone.

Sex-Specific Pharmacokinetics

Women with PCOS who are obese may require higher metformin doses to achieve adequate plasma levels, partly because of altered volume of distribution and renal clearance differences between sexes. Gastrointestinal side effects, which affect 20 to 30 percent of users, are more commonly reported by women than men in observational data, though randomized head-to-head sex comparisons are limited. This is one of many areas where the evidence base in women specifically needs to grow.

Lifestyle Medicine: The Underrated Treatment That Predates Pharma

Before any drug or surgery, weight loss and physical activity were observed to restore ovulation in some women with PCOS. A 5 to 10 percent reduction in body weight in overweight or obese women with PCOS reduces androgen levels, improves insulin sensitivity, and restores ovulation in approximately 55 to 90 percent of previously anovulatory women. No drug has matched that effect size per unit of effort in the right patient.

Why Lifestyle Advice Has Historically Failed Women

"Just lose weight" is not a treatment plan. Women with PCOS face a double metabolic disadvantage: insulin resistance makes fat loss harder, and hyperandrogenism increases visceral adiposity. The advice itself was often delivered without the metabolic context that would make it actionable, and without addressing the psychological burden of PCOS, which carries higher rates of depression, anxiety, and disordered eating than the general population.

The 2023 International Evidence-Based Guideline for PCOS (led by Monash University and endorsed by multiple international societies) recommends that lifestyle intervention be offered to all women with PCOS, framed around health rather than weight, using behavioral strategies rather than caloric restriction alone. Dietary quality matters more than specific macronutrient composition in the current evidence base.

Emerging and Current Treatments: GLP-1 Receptor Agonists and Beyond

The GLP-1 receptor agonist class, developed for type 2 diabetes and later obesity, represents the most significant new treatment direction for PCOS in two decades. Semaglutide and liraglutide improve insulin sensitivity, reduce body weight, lower androgen levels, and in small trials have restored menstrual regularity in women with PCOS who had failed or not tolerated metformin.

What the Data Shows So Far

A 2023 randomized trial published in Fertility and Sterility compared semaglutide 1 mg weekly to metformin 1,500 mg daily in 60 women with PCOS over 12 weeks. Semaglutide produced greater reductions in BMI, testosterone, HOMA-IR, and LH-to-FSH ratio. Menstrual regularity improved in 71 percent of the semaglutide group versus 47 percent in the metformin group. These are preliminary numbers from a small trial. Larger, longer, adequately powered trials in women with PCOS specifically are still needed.

Women with PCOS who are using GLP-1 agonists and do not want pregnancy must use reliable contraception. GLP-1 agonists are not approved for use in pregnancy and should be stopped at least two months before a planned conception attempt, based on current manufacturer guidance and the FDA drug labeling for semaglutide.

Inositol Supplements

Myo-inositol and D-chiro-inositol, naturally occurring compounds involved in insulin signaling, have accumulated a reasonable evidence base in PCOS over the past 15 years. A 2019 meta-analysis of 26 randomized controlled trials found myo-inositol improved menstrual frequency, reduced testosterone, and improved insulin resistance compared to placebo. The effect size is modest, but the safety profile is favorable, making it a reasonable adjunct rather than a replacement for medical treatment in women with mild metabolic dysfunction.

Pregnancy, Lactation, and Contraception in PCOS Treatment

Pregnancy safety is not optional context. It is central to how you and your clinician should approach every PCOS medication decision.

Drugs That Require Contraception

Spironolactone is teratogenic in animal models, with potential feminization of male fetuses. The FDA classifies spironolactone in pregnancy category C/D (older classification) with a clear warning against use in pregnancy. Any woman of reproductive age taking spironolactone needs reliable contraception. This is usually achieved by combining it with a combined oral contraceptive, which also addresses the cycle irregularity and androgen excess of PCOS.

GLP-1 receptor agonists are not approved in pregnancy. Animal data shows fetal harm at supratherapeutic doses. Stop semaglutide or liraglutide at least two months before attempting conception. If pregnancy occurs while on these drugs, discontinue immediately and notify your prescriber.

Drugs Considered Relatively Safe in Pregnancy

Metformin has an extensive human safety record. It crosses the placenta and has been used in gestational diabetes for decades. No increase in congenital malformations has been documented in large observational cohorts. Some clinicians continue metformin through the first trimester in women with PCOS to reduce miscarriage risk, though a 2020 Cochrane review found insufficient evidence that metformin improves live-birth rates in PCOS pregnancies specifically. The decision to continue metformin in pregnancy should be made with your OB-GYN.

Letrozole and clomiphene are used only to induce ovulation and are discontinued once pregnancy is confirmed. Clomiphene has a long human safety record; letrozole's safety data in pregnancy is more limited, though a large registry study found no increase in major congenital anomalies.

Lactation

Metformin transfers into breast milk in small amounts. Based on current pharmacokinetic data, infant exposure is approximately 0.28 percent of the maternal weight-adjusted dose, which most authorities including the NIH LactMed database consider compatible with breastfeeding. Spironolactone transfers in small amounts and is generally considered compatible with breastfeeding by LactMed, though data are limited. GLP-1 receptor agonists have no adequate human lactation data and should generally be avoided while breastfeeding until more information is available.

How Treatment Differs Across Life Stages

Adolescence

Diagnosing PCOS in adolescents requires caution. Irregular cycles and polycystic ovarian morphology are both normal variants in the first two years after menarche. ACOG recommends using a minimum of two years from menarche before applying the Rotterdam criteria in adolescents. Treatment in this life stage focuses on cycle regulation (combined oral contraceptives or cyclic progestins) and metabolic screening. Fertility drugs are not appropriate in adolescents.

Reproductive Years, Not Trying to Conceive

Combined oral contraceptives with a less androgenic progestin (e.g., drospirenone or norgestimate) plus spironolactone for hirsutism and acne is the most widely used regimen. Metabolic monitoring should happen at least annually: fasting glucose, lipid panel, blood pressure, and in women with BMI >30 or family history of diabetes, an oral glucose tolerance test.

Trying to Conceive

Letrozole 2.5 to 7.5 mg on cycle days 3 to 7 is first-line. Clomiphene 50 to 150 mg is an acceptable alternative. Stop hormonal contraception and spironolactone before attempting conception. Add metformin if clomiphene-resistant or if metabolic risk is high. Women with PCOS have higher miscarriage rates than the general population; the rate has been estimated at 20 to 40 percent in some PCOS cohorts, though the exact figure varies by phenotype and study design.

Perimenopause and Post-Menopause

PCOS does not disappear at menopause. Ovarian androgen production continues well into post-menopause in many women. The cumulative metabolic risk, elevated cardiovascular disease risk, type 2 diabetes, and non-alcoholic fatty liver disease, persists and may worsen without ongoing management. A 2020 study in the Journal of Clinical Endocrinology and Metabolism found that postmenopausal women with a history of PCOS had significantly higher triglycerides, lower HDL, and greater carotid intima-media thickness than age-matched controls. Menopausal hormone therapy decisions in women with PCOS should weigh this metabolic background carefully.

Who This Treatment History Is Right (and Wrong) for Knowing

Understanding this history helps you ask better questions of your clinician. A few practical orientations:

If you are primarily bothered by irregular periods and not trying to conceive: A combined oral contraceptive with drospirenone (e.g., Yasmin or Yaz) plus annual metabolic screening is a reasonable starting framework. Adding spironolactone addresses skin and hair symptoms your OB-GYN may not have raised.

If you are trying to conceive and have been told you are not ovulating: Ask specifically for letrozole, not clomiphene, as first-line, based on the 2014 Legro trial data. If your BMI is >30 and insulin resistance is documented, metformin co-treatment may improve your odds.

If your main concern is metabolic risk: Metformin, lifestyle intervention with dietary quality focus rather than caloric restriction alone, and now GLP-1 agonists in appropriate candidates are the tools with the strongest evidence for reducing long-term cardiometabolic risk. Annual glucose tolerance testing is not optional in this context.

If you are in perimenopause or post-menopause: Request cardiovascular risk assessment. Your PCOS history is relevant to your cardiologist and internist, not only your gynecologist.

The evidence gap across all these life stages is real. Women with PCOS have been enrolled in trials largely when they presented for fertility treatment, which means the data is thinnest for post-menopausal PCOS management and for adolescents. What is known has been extrapolated from shorter reproductive-age trials. Your clinician should acknowledge that uncertainty rather than paper over it.